

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-185) MIBAVADEMAB

PRONUNCIATION mye" ba vad' e mab

THERAPEUTIC CLAIM Treatment of generalized lipodystrophy, partial lipodystrophy and obesity with low leptin levels

CHEMICAL NAMES

1. Immunoglobulin G4 [227-proline], anti-(human leptin receptor) (human monoclonal REGN4461 γ 4-chain), disulfide with human monoclonal REGN4461 κ -chain, dimer
2. Immunoglobulin G4-kappa, anti-(*Homo sapiens* Leptin receptor(LEP-R, HuB219, OB receptor, CD295 antigen)); human monoclonal antibody; γ 4 heavy chain (1-446) [*Homo sapiens* VH (IGHV3-30*15 (92%) –(IGHD)-IGHJ2*01) [8.8.12] (1-119) -*Homo sapiens* IGHG4*01 {hinge[S¹⁰>P(227)]} (120-446)] (133-215')-disulfide with κ light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV1-39*01 –IGKJ5*01)[6.3.10] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')], dimer (225-225":228-228")-bisdisulfide

STRUCTURAL FORMULA

Heavy chain

QVQLVESGGG	VVQPGRSLRL	SCAASGFTFS	TYAMYWVRQT	PGKGLEWVAV	50
LYSDGSNKYY	IDSVKGRFTI	SRDTSTNTLY	LQMSLRADD	SALYYCARLN	100
WDYWFYFDLWG	RGTLVTVSSA	STKGPSVFPL	APCSRSTSES	TAALGCLVKD	150
YFPEPVTVSW	NSGALTSGVH	TFFPAVLQSSG	LYSLSSVTV	PSSSLGTKTY	200
TCNVDHKPSN	TKVDKRVESK	YGPPCPPCPA	PEFLGGPSVF	LFPPKPKDTL	250
MISRTPEVTC	VVVDVSQEDP	EVQFNWYVDG	VEVHNAKTKP	REEQFNSTYR	300
VVSVLTVLHQ	DWLNKEYK	KVSNKGLPSS	IEKTIKAKG	QPREPQVYTL	350
PPSQEEMTKN	QVSLTCLVKG	FYPSDIAVEW	ESNGQPENNY	KTTTPVLDS	400
GSFFLYSRLT	VDKSRWQEGN	VFSCSVMHEA	LHNHYTQKSL	SLSLGK	446

Heavy chain

DIQMTQSPSS	LSASVGDRVT	ITCRASQGIS	SYLNWYQQK	GKAPKLLIYA	50'
ASSLQSGVPS	RFSGSGSGTD	FTLTISSLQP	EDFATYYCQ	SYSTPPITFG	100'
QGTRLEIKRT	VAAPSVFIFP	PSDEQLKSGT	ASVVCLLN	YPREAKVQWK	150'
VDNALQSGNS	QESVTEQDSK	DSTYLSSTL	TLSKADYEKH	KVYACEVTHQ	200'
GLSSPVTKSF	NRGEC				215'

Disulfide bridges

22-96	22"-96"	23'-88'	23"-88"	135'-195'	235"-195"	133-215'	133"-215"
146-202	146"-202"	225-225"	228-228"	260-320	260"-320"	366-424	366"-424"

Deleted residues

K
446, 446"

Glycosylation sites (N)

Asn-296 Asn-296"

MOLECULAR FORMULA C₆₄₇₂H₉₉₆₆N₁₇₁₀O₂₀₂₈S₄₄ . (non glycosylated)

MOLECULAR WEIGHT 145.59 kDa

TRADEMARK	None as yet
SPONSOR	Regeneron Pharmaceuticals Inc.
CODE DESIGNATIONS	REGN4461
<u>CAS</u> REGISTRY NUMBER	2305770-44-7
UNII	PHL2UDY3AB
WHO NUMBER	11510

gbk